Cargando…
Improving Localized Radiotherapy for Glioblastoma via Small Molecule Inhibition of KIF11
SIMPLE SUMMARY: Glioblastoma, IDH-wild type (GBM) is the most common malignant primary brain tumor. Advances in cancer therapy remain unsuccessful in the treatment of GBM patients and have not extended the median survival beyond 12–18 months with the current treatment of surgery, chemotherapy, and r...
Autores principales: | Tallman, Miranda M., Zalenski, Abigail A., Stabl, Ian, Schrock, Morgan S., Kollin, Luke, de Jong, Eliane, De, Kuntal, Grubb, Treg M., Summers, Matthew K., Venere, Monica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296095/ https://www.ncbi.nlm.nih.gov/pubmed/37370783 http://dx.doi.org/10.3390/cancers15123173 |
Ejemplares similares
-
An interphase pool of KIF11 localizes at the basal bodies of primary cilia and a reduction in KIF11 expression alters cilia dynamics
por: Zalenski, Abigail A., et al.
Publicado: (2020) -
Capitalizing on ATRX loss in glioma via PARP inhibition: Comment on “Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity” by Garbarino et al.
por: Zalenski, Abigail A, et al.
Publicado: (2021) -
KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain?
por: Valensin, Silvia, et al.
Publicado: (2009) -
Prognostic Significance of KIF11 and KIF14 Expression in Pancreatic Adenocarcinoma
por: Klimaszewska-Wiśniewska, Anna, et al.
Publicado: (2021) -
Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma
por: Matsui, Jennifer K., et al.
Publicado: (2022)